RAPT THERAPEUTICS INC (RAPT)
US75382E1091 - Common Stock
Overall RAPT gets a fundamental rating of 2 out of 10. We evaluated RAPT against 565 industry peers in the Biotechnology industry. RAPT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. RAPT does not seem to be growing, but still is valued expensively.
1. Profitability
1.1 Basic Checks
RAPT had negative earnings in the past year.
In the past year RAPT has reported a negative cash flow from operations.
RAPT had negative earnings in each of the past 5 years.
In the past 5 years RAPT always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -67.38%, RAPT is not doing good in the industry: 64.23% of the companies in the same industry are doing better.
RAPT has a Return On Equity (-79.43%) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.38% | ||
| ROE | -79.43% | ||
| ROIC | N/A |
ROA(3y)-44.57%
ROA(5y)-45.8%
ROE(3y)-50.25%
ROE(5y)-52.07%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
RAPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
RAPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for RAPT has been increased compared to 1 year ago.
The number of shares outstanding for RAPT has been increased compared to 5 years ago.
There is no outstanding debt for RAPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
RAPT has an Altman-Z score of -4.71. This is a bad value and indicates that RAPT is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of RAPT (-4.71) is worse than 60.68% of its industry peers.
RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.71 |
ROIC/WACCN/A
WACC10.91%
2.3 Liquidity
A Current Ratio of 7.41 indicates that RAPT has no problem at all paying its short term obligations.
RAPT has a Current ratio of 7.41. This is in the better half of the industry: RAPT outperforms 70.28% of its industry peers.
A Quick Ratio of 7.41 indicates that RAPT has no problem at all paying its short term obligations.
RAPT's Quick ratio of 7.41 is fine compared to the rest of the industry. RAPT outperforms 70.28% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.41 | ||
| Quick Ratio | 7.41 |
3. Growth
3.1 Past
The Earnings Per Share has been growing slightly by 3.82% over the past year.
The Revenue for RAPT has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)3.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.68%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
Based on estimates for the next years, RAPT will show a decrease in Earnings Per Share. The EPS will decrease by -2.06% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y16.66%
EPS Next 2Y17.59%
EPS Next 3Y17.87%
EPS Next 5Y-2.06%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
RAPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RAPT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as RAPT's earnings are expected to grow with 17.87% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y17.59%
EPS Next 3Y17.87%
5. Dividend
5.1 Amount
RAPT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
RAPT THERAPEUTICS INC
NASDAQ:RAPT (12/23/2024, 8:00:01 PM)
After market: 1.6602 -0.08 (-4.59%)1.74
+0.91 (+110.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners92.11%
Inst Owner Change-5.83%
Ins Owners1.9%
Ins Owner Change0%
Market Cap60.83M
Analysts53.33
Price Target2.72 (56.32%)
Short Float %4.07%
Short Ratio2.24
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.97%
Min EPS beat(2)-6.73%
Max EPS beat(2)8.68%
EPS beat(4)2
Avg EPS beat(4)2.4%
Min EPS beat(4)-9.57%
Max EPS beat(4)17.22%
EPS beat(8)6
Avg EPS beat(8)5.09%
EPS beat(12)9
Avg EPS beat(12)4.54%
EPS beat(16)11
Avg EPS beat(16)3.24%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-66.67%
PT rev (3m)-71.43%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)2.2%
EPS NY rev (3m)1.28%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.41 | ||
| P/tB | 0.41 | ||
| EV/EBITDA | N/A |
EPS(TTM)-2.77
EYN/A
EPS(NY)-1.88
Fwd EYN/A
FCF(TTM)-2.81
FCFYN/A
OCF(TTM)-2.78
OCFYN/A
SpS0
BVpS4.21
TBVpS4.21
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -67.38% | ||
| ROE | -79.43% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-44.57%
ROA(5y)-45.8%
ROE(3y)-50.25%
ROE(5y)-52.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 92.52% | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 7.41 | ||
| Quick Ratio | 7.41 | ||
| Altman-Z | -4.71 |
F-Score2
WACC10.91%
ROIC/WACCN/A
Cap/Depr(3y)83.16%
Cap/Depr(5y)70.42%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)3.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%42.68%
EPS Next Y16.66%
EPS Next 2Y17.59%
EPS Next 3Y17.87%
EPS Next 5Y-2.06%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-48.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.86%
EBIT Next 3Y8.84%
EBIT Next 5YN/A
FCF growth 1Y-37.07%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.13%
OCF growth 3YN/A
OCF growth 5YN/A